THALLOUS CHLORIDE TL 201
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
THALLOUS CHLORIDE TL 201 by GE HealthCare is 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. First approved in 1982.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Thallous Chloride Tl 201 is a radiopharmaceutical diagnostic agent approved in 1982 that accumulates in viable myocardium analogous to potassium, enabling visualization of regional myocardial perfusion and infarction. It is administered via injection and used to detect areas of myocardial ischemia and infarction, particularly during exercise stress testing. The drug's distribution correlates with coronary blood flow, allowing identification of transient ischemia in stenosed coronary arteries.
LOE Approaching
This product faces LOE pressure with moderate competitive intensity (30%), indicating shrinking market opportunity and likely contraction of the brand team.
Mechanism of Action
201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Thallous Chloride Tl 201 offers exposure to diagnostic product management and mature-market strategy within a stable specialty imaging portfolio. However, the LOE-approaching lifecycle means limited growth opportunities and potential role compression as the product enters post-LOE phases.
Worked on THALLOUS CHLORIDE TL 201 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.